Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This is according to two studies of real-world use of the hepatitis C regimen.
This finding is from a program that sought to provide blanket treatment to Iceland’s hep C population.
A new meta-analysis finds this population has a high success rate on hepatitis C therapy.
Researchers reviewed numerous studies to inform their detailed tips for better engaging people who inject opioid drugs in hepatitis C care.
After a reformulated version of the opioid painkiller hit the market in 2010, some with opioid use disorder migrated from pills to heroin.
A trio of British studies projected the impact of programs that provide clean injection-drug materials to people who inject drugs.
Existing federal law could permit prisons to negotiate a 90 percent–plus discount—without scaring off pharma.
Researchers say given the many associated downsides and risks, opioids should not be a first choice for chronic noncancer pain.
A recent survey of such sites found high rates of hepatitis C among patrons, but treatment for the virus was rarely offered on-site.
Researchers analyzed data resulting from a uniform hepatitis C testing policy in Washington state’s correctional facilities.
The generally false presumption that they won’t adhere to the regimen is often used to deny coverage for hep C medications.
Researchers modeled the differences between testing focused on baby boomers versus universal screening.
Baby boomers still make up the largest bloc of those with the virus, but youths’ injection drug use is sending their infection rates upward.
Using opioid medication treatment such as methadone appears to lower this risk.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.